RGNX - REGENXBIO Inc.
| Previous Close | 43.00 |
| Open | 42.76 |
| Bid | 42.23 x 1100 |
| Ask | 42.45 x 2200 |
| Day's Range | 41.71 - 43.76 |
| 52 Week Range | 38.56 - 85.10 |
| Volume | 238,976 |
| Avg. Volume | 588,861 |
| Market Cap | 1.555B |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.05 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.79 |
- PR Newswire•7 days ago
REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
ROCKVILLE, Md., May 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced its plan to construct a current good manufacturing practice (cGMP) production facility, to be located in Rockville, Maryland. The new cGMP production facility will be integrated into REGENXBIO's previously announced new 132,000 square foot headquarters, for which construction is currently underway, and will allow for production of NAV Technology-based vectors at scales up to 2,000 liters using REGENXBIO's platform suspension cell culture process. The facility will be designed to meet global regulatory requirements and is expected to be operational in 2021.
- PR Newswire•14 days ago
REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
ROCKVILLE, Md. , May 8, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
Motley Fool•15 days agoRegenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
- Associated Press•15 days ago
Regenxbio: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 89 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- PR Newswire•15 days ago
REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md. , May 7, 2019 /PRNewswire/ -- Reports positive interim update from RGX-314 Phase I/IIa trial for wet AMD in Cohort 3 over one year Announces new IND submission for RGX-314 for a Phase II ...
- Insider Monkey•20 days ago
Is Regenxbio Inc (RGNX) A Good Stock To Buy?
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- PR Newswire•22 days ago
REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Investor's Business Daily•last month
A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock
A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday. Regenxbio lost nearly 8% by the closing bell.
- Motley Fool•last month
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Simply Wall St.•last month
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
- PR Newswire•last month
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
ROCKVILLE, Md., April 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Steve Pakola, M.D., as its Senior Vice President and Chief Medical Officer. Dr. Pakola will report to Kenneth T. Mills, REGENXBIO's President and Chief Executive Officer.
- PR Newswire•last month
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
ROCKVILLE, Md. , April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•last month
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- Motley Fool•2 months ago
3 Small-Cap Biotech Stocks to Watch Now
These under-the-radar stocks could be poised to make big moves in the coming months.
- GlobeNewswire•2 months ago
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investopedia•2 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Motley Fool•2 months ago
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Roche and Biogen are spending big bucks on gene therapy biotech stocks.
- PR Newswire•3 months ago
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•3 months ago
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Motley Fool•3 months ago
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- Barrons.com•3 months ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Regenxbio Inc Earnings Call
Motley Fool•3 months agoRegenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
RGNX earnings call for the period ending December 31, 2018.
